Efficacy and Safety of Moxifloxacin 0.5% Eye Drops versus Tobramycin 0.3% Eye Drops in Pediatric Population with Purulent Bacterial Conjunctivitis
Loading...
Date
2019-05
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
International Research Organization for Life & Health Sciences (IROLHS)
Abstract
Aims: The study aims to determine the efficacy and safety of moxifloxacin 0.5% eye drops versus tobramycin 0.3% eye dropsin pediatric population with purulent bacterial conjunctivitis.Study design: Prospective, randomized, investigator-masked, clinical study was conducted on patients.Place and Duration of Study: This study was conducted by the Department of Ophthalmology Veer Chandra Singh GarhwaliGovernment Medical College, Srinagar, Uttarakhand, between March 2018 and February 2019.Methodology: This study included 100 children with purulent discharge and bulbar conjunctival injection. Children either receivedmoxifloxacin 0.5% 4 times a day for 5 days or received tobramycin 0.3% eye drops (every 2 h for 2 days and then 4 times for5 days). Clinical signs were evaluated on days (D) 0, 3, and 7 and cultures on D0 and D7. The primary variable was the clinicalcure (absence of bulbar injection and discharge) on D3 in the worst eye for patients with positive culture on D0.Results: 100 culture-positive cases were included on D0. Moxifloxacin was superior to tobramycin in clinical cure rate on D3 (47.1%vs. 28.7%) P = 0.013) and was non-inferior to tobramycin on D7 (89.8% vs. 78.2%, respectively). Moxifloxacin treatment eradicatedcausative pathogens, including resistant species with a similar resolution rate to tobramycin (89.8% vs. 87.2%).Conclusion: Moxifloxacin 0.5% eye drops provided a more rapid and effective clinical cure than tobramycin 0.3% eye dropsin the treatment of purulent bacterial conjunctivitis in children, with 4 times dosing.
Description
Keywords
Bacterial, Conjunctivitis, Moxifloxacin, Tobramycin
Citation
Koul Prateek, Gupta Vijayta. Efficacy and Safety of Moxifloxacin 0.5% Eye Drops versus Tobramycin 0.3% Eye Drops in Pediatric Population with Purulent Bacterial Conjunctivitis. International Journal of Scientific Study. 2019 May; 7(2): 89-92